The clinical trial result of HLB’s targeted anticancer medicine rivoceranib will be presented at the 2022 International Association for the Study of Lung Cancer (IASLC 2022), the company said Thursday.IASLC, the world’s largest symposium for lung cancer and other thoracic malignancy, will be held in
Fears of Covid-19 resurgence are spreading, but SK Bioscience has yet to apply for a lot release of SKYCovione, the first homegrown Covid-19 vaccine.On Wednesday, SK Bioscience confirmed SKYCovicone’s immune response to the Omicron variant BA.1 in extended phase 1 and 2 trials.The company gave two d
SK Biopharmaceuticals said it signed a $62 million licensing agreement to commercialize cenobamate (brand name: Xcopri), an anti-epileptic treatment, in Latin America.In a public filing on Thursday, the company said it licensed out cenobamate to Eurofarma Laboratorios SA for the commercialization of
MSD’s anti-PD-1 therapy Keytuda (pembrolizumab) won expanded indication to be used as neoadjuvant therapy in combination with chemotherapy before surgery in patients with triple-negative breast cancer (TNBC) and then continued as a single agent after surgery.This indication allows Keytruda to treat
GemVax & Kael, an immunotherapy drug developer, said on Wednesday that the company had secured safety in the non-clinical toxicity trials of GV1001, the company’s 16-amino-acid peptide immunotherapy drug for pancreatic cancer.New substances generally require various strict conditions to be met to be
Bridge Biotherapeutics will present the phase 1 clinical trial’s result of BBT-176, the fourth-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) drug, at the World Conference on Lung Cancer (WCLC) in Vienna next month.The conference organizers made public the abstract
Biomarker-based new drug developer MedPacto has applied to the U.S. Food and Drug Administration for the investigational new drug (IND) clinical trial of Vactosertib as a solo therapy for recurrent and intractable osteosarcoma patients.This upcoming clinical trial, a phase 1/2 trial of Vactosertib a
Neoimmuntech said Wednesday that the U.S. Food and Drug Administration has granted an orphan drug designation (ODD) for NT-I7, its immunotherapy candidate that treats glioblastoma multiforme (GBM), a type of brain cancer.It was the fourth ODD designation for NT-I7. It also received ODD designations
SK Bioscience’s SKYCovione, Korea's first locally developed Covid-19 vaccine, has shown cross-neutralizing activity against Omicron variant BA.1 as a booster shot administered after the primary vaccination, the company said Wednesday."Amid the rising possibility of the resurgence of Covid-19, we hav
Boehringer Ingelheim and Eli Lilly aim to dominate the chronic heart failure market with Jardiance, a Sodium-Glucose Co-Transporter 2 (SGLT-2) inhibitor drug, armed with an expanded indication in treating heart failure with preserved ejection fraction (HFpEF).HFpEF is a clinical syndrome in which pa
Korea’s daily Covid-19 tally surged to a two-month high of over 37,000 on Tuesday, as the BA.5, an Omicron subvariant, showed signs of becoming a dominant strain.The nation added 37,360 Covid-19 infections on Tuesday, bringing the total caseload to 18,561,861, the Korea Disease Control and Preventio
CBC Group, a Singapore-based venture capital firm that invests in medical and pharmaceutical companies, may fully acquire Hugel and take the company private, Bloomberg reported.A person familiar with the matter, asking for anonymity due to the issue's sensitivity, told the media outlet that CBC is i
Kainos Med said it would start phase 2 clinical trials in the U.S. by administering its Parkinson's disease treatment, KM-819, to subjects.KM-819 is a new drug developed by Kainos Med, which targets FAF, a protein that promotes cell death. It has a dual effect of inhibiting the accumulation of alpha
Sanofi’s fitusiran is called “the dream hemophilia treatment” because it can be used in all hemophilia A or B patients regardless of whether they have inhibitors. In addition, the investigational drug recently proved its prophylaxis effect in a phase 3 study.However, fitusiran reported two thromboem
CHA Vaccine Institute said Monday it has confirmed the immuno-cancer treatment effect of L-pampo, an immuno-cancer drug candidate that stimulates the toll-like receptor (TLR) signal pathway, developed by the institute independently.The institute, jointly with Professors Chon Hong-jae and Kim Chan of
Daiichi Sankyo Korea has received approval from the Ministry of Food and Drug Safety for an additional indication for Taleaje (Ingredient: mirogabalin), a neuropathic pain treatment, in treating central neuropathic pain.Taleaje had previously received approval to treat peripheral neuropathic pain in
JW Pharmaceutical said it has launched a compound digestive medicine, Besticon, and begun marketing activities in earnest.Besticon is a compound digestive medicine composed of alverine citrate, an antispasmodic agent, and simethicone, a degassing agent. It is effective on functional indigestion and
Celltrion Pharm’s prescription liver disease treatment Godex Cap. might lose reimbursement because the Health Insurance Review and Assessment Service (HIRA) recently decided to withdraw its insurance benefits. The company appealed the decision immediately.HIRA disclosed the results of the drug reimb
Hugel said Friday that it has obtained product approval from the Spanish Agency of Drugs and Health Products for its botulinum toxin (BTX) formulation, Letybo, which treats forehead wrinkles.With the product approved in Spain, Hugel has obtained a license in 11 European countries. Spain is one of th
The unionized workers of Novo Nordisk Korea held a protest rally in front of the company’s headquarters in southern Seoul on Thursday, after the breakdown of negotiations over wages and cuts in employee incentives.Out of the total 118 unionists, 100 participated in the protest rally, excluding those